Summary Aminoguanidine, a nucleophilic hydrazine, has been shown to be capable of blocking the formation of advanced glycation end products. It reduces the development of atherosclerotic plaques and prevents experimental diabetic nephropathy. We have'found that aminoguanidine is also quite potent at inhibiting semicarbazide-sensitive amine oxidase (SSAO) both in vitro and in vivo. The inhibition is irreversible. This enzyme catalyses the deamination of methylamine and aminoacetone, which leads to the production of cytotoxic formaldehyde and methylglyoxal, respectively. Serum SSAO activity was reported to be increased in diabetic patients and positively correlated with the amount of plasma glycated haemoglobin. Increased SSAO has also been demonstrated in diabetic animal models. Urinary excretion of methylamine is substantially increased in the rats following acute or chronic treatment with aminoguanidine. Urinary methylamine levels were substantially increased in streptozotocin (STZ)-induced diabetic rats following administration of aminoguanidine. The non-hydrazine SSAO inhibitor (E)-2-(4-fluorophenethyl)-3-fluoroallylamine hydrochloride (MDL-72974A) has been shown to reduce urinary excretion of lactate dehydrogenase (an indicator of nephropathy) in STZ-induced diabetic rats. Formaldehyde not only induces protein crosslinking, but also enhances the advanced glycation of proteins in vitro. The results support the hypothesis that increased SSAOmediated deaminafion may be involved il~ structural modification of proteins and contribute to advanced glycation in diabetes. The clinical implications for the use of aminoguanidine to prevent glycoxidation have been discussed.
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Glucose reacts chemically with the amino groups of amino acids or nucleic acids to form Amadori products [1] , which then rearrange into advanced glycation end products (AGEs) [2] . This process leads to marked changes in the structure and function of various proteins. The formation of AGEs from the Amadori product is also known to occur via an oxidative process [3] . It is accelerated in the presence of transition metals and is reduced by ascorbate [4, 5] , suggesting that the reaction is mediated by free radicals [6] . There is accumulating evidence that the formation of AGEs increases with aging [7] and is implicated in the pathogenesis of diabetic atherosclerosis [2] . AGEs can crosslink with collagen and other structural and functional proteins [1] . This increases the rigidity of collagen, decreases arterial compliance, and enhances hypertension [8, 9] . Advanced glycated collagen is capable of covalently trapping LDL [10] . LDL, once trapped in the arterial wall, is susceptible to attack by free radicals and subject to oxidative modification [11] . AGEs may also affect monocyte migration and induce an inflammatory response [12, 131.
Aminoguanidine reacts with Amadori fragmentation products and thus prevents glycation and AGE formation [14] . It prevents experimental diabetic nephropathy [15] and inhibits lipid peroxidation in vivo [16] . It also blocks the oxidative modification of LDL and its subsequent uptake by macrophages in a euglycaemic in vitro system [17] . The drug can reduce the development of atherosclerotic plaque without altering serum cholesterol levels in cholesterol-fed rabbits [18] , urinary albumin excretion in diabetic rats [19] and regional albumin clearance [20] .
Aminoguanidine is a nucleophilic hydrazine. It is well known that hydrazine compounds are capable of interacting with carbonyl groups of different biological constituents, such as glucose, pyridoxal, 6-hydroxydopa and pyrroloquinolinone quinone enzyme cofactors} etc. SSAO is an enzyme that possesses 6-hydroxydopa as a cofactor, and is quite sensitive to hydrazines. We therefore investigated whether aminoguanidine inhibits SSAO activity. This enzyme catalyses the deamination of methylamine, for example, and produces toxic formaldehyde and hydrogen peroxide [21, 22] . Serum SSAO activity has been found to be substantially increased in diabetes and patients with liver diseases [23] [24] [25] [26] . A significant positive correlation between SSAO activities and plasma glycated haemoglobin levels was observed [26] . SSAO activity has also been found to be increased in the blood and kidney of diabetic rats (streptozotocin [STZ]-treated) [27] and diabetic sheep (alloxantreated) [28] . Deamination of methylamine by serum SSAO is cytotoxic to endothelial cells in vitro and SSAO inhibitors block this toxicity [29] ; It has been proposed that excessive deamination of methylamine may be involved in the initiation of endothelial injury and be related to diabetic complications [29] . In the present study we describe the inhibition of SSAO by aminoguandine and the possible involvement of SSAO in advanced glycation. Alternative actions of aminoguanidine are discussed.
Materials and methods
Materials. Human umbilical cords were kindly provided by the Department of Obstetrics and Gynecology, Royal University Hospital, Saskatoon. Benzylamine, aminoguanidine bicarbonate, methylamine hydrochloride, horseradish peroxidase, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and semicarbazide hydrochloride were purchased from Sigma, (St. Louis, Mo., USA). Animal experiments. Male Wistar rats (200 g) were used in the experiments. The animal treatments were in strict accordance with the guidelines established by the Canadian Council on Animal Care and were approved by the University of Saskatchewan Animal Care Committee. The rats were housed in hanging wire cages with free access to food and water on a 12 h light/dark cycle (lights on 06.00 hours) at a temperature of 19-20~ Diabetes was induced in animals by a single administration of STZ (60 mg/kg, i.p.). Serum glucose levels were assessed in order to ensure that diabetes was induced. The blood glucose levels of the control and STZ-induced diabetic rats were 1.61 + 0.04 (mean _+ SEM) and 4.74 + 0.35 mg/ ml (from 3.3 to 7.5 mg/ml) respectively. Aminoguanidine (10 mg/kg) was administered daily via intraperitoneal injection for 3 weeks. The aminoguanidine treatment was then maintained by including the drug in the drinking water (1 mg/ml). The control animals were injected with saline and supplied with tap water. Twenty-four-hour urine was collected with metabolic cages at 24 h, 1 week, 3 week and 7 weeks after the initial aminoguanidine treatment.
Preparation of SSA 0 from rat aorta and human umbilical artery. SSAO from human umbilical artery [29] and rat aorta [30] was prepared as previously described. Tissues were thoroughly rinsed with saline, sliced into small pieces and homogenized with a Polytron homogenizer (PT-10-35, at setting 5 for four periods of 5 s on ice) in chilled 0.01 mol/l phosphate buffer (pH 6.8). The crude homogenates were centrifuged at 800 g for 10 rain and the supernatants further centrifuged at 32000 g for 30 min. These final supernatant enzyme preparations were either used immediately or stored at -70 ~ The enzymes were quite stable under these conditions for at least I month.
Determination of SSAO activity. SSAO activity was determined by a radio-enzymatic procedure using 14C-labelled benzylamine as substrate following our previously described procedure [29] . The SSAO enzyme preparations were pre-incubated with clorgyline (1 x 10 -4 mol/l) at room temperature for 20 rain to ensure that any monoamine oxidase activity, if present, was completely inactivated. The enzyme was then incubated in the presence of benzylamine (5 x 10 -5 mol/1, 0.1 ~tCi) in a final volume of 200/xl at 37 ~ for 30 min. The enzyme reaction was terminated by adding 200 ~tl 2 mol/1 citric acid. The oxidized products were extracted into 1 ml toluene:ethyl acetate (1:1, v/v), of which 600 Ixl was then transferred to a counting vial containing 10 ml Omnifluor cocktail (New England Nuclear, Boston, Mass., USA). Radioactivity was assessed by liquid scintillation counting (Beckman LS-7500, Fullerton, Calif., USA). One unit of enzyme activity is defined as one nanomole of product formed per min per mg of protein.
Determination ofmethylamine. Urinary methylamine was determined using an HPLC-fluorometric procedure, lsopropylamine was added as an internal standard to the urine immediately after its collection and the samples were stored at -70 ~ until use. Urine samples (0.5 ml) were pre-purified by application to a small column of CG-50 amberlite (0.5 x 2.5 cm), rinsed with 10 ml water and the amines then eluted with 2 ml 1 mol/1 HCI. The samples (100 ~tl) were derivatized with ophthaldialdehyde (OPA)(100 ~tl) under alkaline conditions (pH 10.4), and 50 ~tl of the derivatized sample eluates were separated in a Shimadzu HPLC system (Sil-9A auto injector; Tokyo, Japan) equipped with a pre-column derivatization program. The fluorescent amine derivatives were separated in an analytical Ultrasphere I.E column packed with octadecylbonded spherical-5 micron silica particles (250 x 4.6 mm internal diameter) (Beckman, Toronto, Ontario, Canada). The column was eluted with 55 % methanol at a flow rate of 1.0 ml/ rain using a SSI 222B solvent delivery system (State College, Pa., USA). For quantitative assessment, a programmable fluorescence detector (Hewlett Packard, HPt046A, Mississauga, Ontario, Canada) with excitation at 360 nm and emission at 445 nm was employed. The signals of peak area were integrated using a Spectra-Physics SP-4290 integrator. The retention times for methylamine and iso-propylamine are 11.9 and 29.2 min, respectively. The recovery of methylamine from the ion exchange chromatography was approximately 80 %. The peak ratios of methylamine/isopropylamine (internal standard) were used for the calculation of urine levels of methylamine.
Determination of urinary LDH activity. The assay is based on the production of NADH from nicotinamide adenine dinucleotide (NAD +) during the conversion of lactate to pyruvate by LDH. NADH was measured spectrophotometricalIy at 340 nm. All assays were performed in 96-well plates. An aliquot of urine (50 txl) was incubated in the presence of 50 ~tl NAD* (1 mg/ml) and 100 F1 lactate (1%) in 0.05 tool/1 phosphate buffer, pH 9.0. The rates of NADH formation (milli-optical density per rain [roOD/rain]) were monitored using a UVmax kinetic microplate reader (Molecular Devices, Menlo Park, Calif., USA).
Protein glycation in vitro.
In vitro glycation was estimated according to Edelstein and Brownlee [14] . The glycation reactions were conducted at 37 ~ in 0.08 tool/1 sodium phosphate buffer (pH 7.8) containing 0.12 mg/ml penicillin-G, 0.1 mg/ml gentamiein, 0.25 ixg/ml fungazone, 0.02 mg/ml polymyxin B, i mmol/l EDTA and 1 mmol/l phenylmethylsulphonyl fluoride. RNase (10 mg/ml) was incubated for different time periods with 0.5 mol/1 glucose in the presence or absence of formaldehyde (0.005 %). AGE formation was determined fiuorospectrometrically at an excitation-emission wavelength of 370/450 nm.
Statistical analysis. The results were assessed using analysis of variance (ANOVA) followed by Newman-Keuls multiple comparisons. In general, the null hypothesis used for all analyses was that the factor has no influence on the measured variable and significance was accepted at the over 95 % confidence level.
Results
Inhibition of SSA 0 activity by aminoguanidine in vitro. As can be seen from Figure 1 , aminoguanidine is quite potent at inhibiting the activities of SSAO obtained from both human umbilical arteries and rat aortae. The IC50 values were estimated to be 1 x 10 -5 and 2 x 10 -5 mol/1 with respect to the rat aorta and the human umbilical enzymes. Effect of aminoguanidine on rat kidney and aorta SSAO in vivo, The SSAO activity in rat kidney and aorta was determined 3 h after a single injection of various doses of aminoguanidine. As can be seen from Figure 2 , SSAO activity is significantly inhibited by the drug in both tissues. The EDs0 values were estimated to be 10 and 5 mg/kg i.p. injection for the rat kidney and aorta SSAO, respectively.
Mode of inhibition of human umbilical SSA O by aminoguanidine. The inhibition of human umbilical
SSAO activity by aminoguanidine was quite fast. Approximately 90 % of the activity was inhibited without preincubation of the enzyme with aminoguanidine; complete inhibition could be obtained with a 15 min preincubation. After incubation of the enzyme with aminoguanidine for 30 min, the unreacted inhibitor was removed by gel filtration through a small Sephadex G-25 column (PD-10, Pharmacia). SSAO activity was not recovered after the gel filtration. Untreated SSAO activity was recovered after the same procedure, thus indicating that the inhibition of SSAO activity by aminoguanidine is irreversible.
Effect of aminoguanidine on methylamine excretion.
A single dose of aminoguanidine (25 mg/kg) was administered to rats and the total urine excreted during the following 24 h collected. The level of methylamine, a typical SSAO substrate, in the urine, was significantly increased. The urinary level of methylamine after treatment with aminoguanidine is quite comparable to that from animals treated with the potent selective SSAO inhibitor MDL-72974A (2 mg/ kg) [291 (Fig. 3) . Fig.3 . Effect of aminoguanidine and the selective SSAO inhibitor MDL-72974A on urinary methylamine levels in rats. Aminoguanidine (25 mg/kg), MDL-72974A (2 mg/kg) and saline were administered i.p. to rats and then 24 h urine was collected. Methylamine was assessed by an HPLC-fluorometric procedure as described in Methods. Creatinine was determined using the picric acid method. Values are mean + SEM of three animals at each dose; * p < 0.01
Chronic effect of aminoguanidine on methylamine excretion in control and diabetic rats. As can be seen from Figure 4 the urinary excretion of methylamine substantially increased at 1, 3 and 7 weeks after chronic aminoguanidine treatment in b o t h control and diabetic rats. The increase ranged from 5-to 10-fold based on either total methylamine excretion. 24 -1 9 rat -1 (Fig. 4, upper panel) or per mg creatinine (Fig.4, lower panel) . The magnitude of increase of methylamine excretion was much more pronounced following chronic treatment than a single acute treatment (Fig.3) , indicating that multiple treatments with aminoguanidine may produce cumulative and complete inhibition of SSAO activity.
The total methylamine excretion was slightly increased in the STZ-induced diabetic rats without aminoguanidine treatment (but only significant at 7 weeks). When SSAO activity was blocked by aminoguanidine, however, the methylamine levels were significantly higher in the STZ-induced diabetic rats at different time following aminoguanidine treatment. There was a trend toward further increase of methylamine excretion in the diabetic animals with prolonged illness.
Effect of chronic treatment of SSAO inhibitor on the urinary excretion of LDH. Urinary L D H has been
used as a marker of nephropathy [31] . As can be seen from Table 1 its activity was not detected in the control rats, but became detectable by the fourth week and further increased by week 12 in STZ-induced diabetic rats. MDL-72974A was found to reduce the urinary excretion of L D H after 4 weeks of Fig.4 . Subchronic effect of aminoguanidine (AG) on urinary methylamine levels in diabetic and control rats. Aminoguanidine (10 mg. kg -1. day -1) and saline were administered i.p. daily to rats for 3 weeks. The animals were continuously orally treated with aminoguanidine (i. e. the drug was included in the drinking water [1 mg/ml]). Twenty-four h urine was collected in 0.05 N HC1 at 1 week and 3 and 7 weeks after aminoguanidine treatment. Internal standard isopropylamine was added to each sample and the urine was kept frozen at -70 ~ until assay. Methylamine was assessed by an HPLC-fluorometrie procedure as described in Methods. Creatinine was determined using the picric acid method. Values are mean + SEM of six animals in each group; a) significantly different from the corresponding aminoguanidine untreated controls; b) significantly different from the corresponding non-diabetic controls At the end of weeks 1, 4 and 12, a 24 h urine was collected from each animal. The assay of LDH activity is described in the Methods. ap < 0.01, in comparison to controls; bp < 0.025 in comparison to STZ group. Number of experimental animals indicated in parentheses. Statistics were performed using twoway ANOVA followed by Newman-Keuls multiple comparisons treatment in the diabetic rats. MDL-72974A alone was, however, also shown to increase the urinary LDH in the rats following 12 weeks of chronic treatment. MDL-72974A does not affect blood glucose (result not shown).
EffeCt or formaldehyde on protein glycation in vitro.
Bovine RNase was incubated with glucose in the absence or presence of a small amount of formaldehyde (0.008%). The degree of advanced glycation was monitored on different days. As shown in Figure 5 , formaldehyde induced a twofold increase in advanced glycation, while formaldehyde by itself did not seem to form any fluorescent adducts with the bovine RNase.
Discussion
The results clearly indicate that aminoguanidine is a potent, irreversible inhibitor of human and rat SSAO both in vitro and in vivo. SSAO is a copper-dependent enzyme and probably possesses a 6-hydroxydopa (or pyridoxal, pyrroloquinoline quinone) moiety as cofactor [32] . As indicated in Figure 6 aminoguanidine, as is the case for other hydrazines [33] , can react with the 3-keto group of the phenyl ring of 6-hydroxydopa (as well as pyridoxal or pyrroloquinoline quinone groups) and form covalently a hydrazone adduct. The enzyme is therefore irreversibly inactivated by aminoguanidine. Aminoguanidine blocks advanced protein glycation in vitro [14] . Whether or not this drug also inhibits advanced glycation in vivo remains to be clarified. Nevertheless aminoguanidine significantly reduces STZ-induced albuminuria [19] , regional albumin clearance [20] , lipid peroxidation in vivo [16] , and it retards the development of experimental diabetic nephropathy [15] . These studies not only indicate the importance of the formation of AGEs in the aetiology of complications associated with diabetes, but also indicate that the prevention of the formation of AGEs may be a useful way of ameliorating diabetic complications. In these in vivo studies multiple daily doses of aminoguanidine (i. e. from 25 to 50 mg/kg) were used [15, 16, [18] [19] [20] 34] . We have shown that a single dose of aminoguanidine (10mg/kg) almost completely blocks aorta and partially blocks kidney SSAO activity in rats. There is little doubt that the multiple large doses of aminoguanidine, that were employed in those previous studies, would effectively inhibit SSAO activity. We have shown that aminoguanidine administered chronically caused a substantially greater increase of methylamine excretion, a typical SSAO substrate (Fig. 4) than a single acute treatment. A complete inhibition of SSAO activity was detected after such chronic treatment (results not shown).
Aminoguanidine has also been found to inhibit nitric oxide synthase [35] . Nitric oxide production seems to be involved in the pathogenesis of early diabetic vascular dysfunction and inhibition of its activity by aminoguanidine was proposed to be related to the prevention of AGE formation [36] . The in vivo effects of aminoguanidine seem to be more complicated than simply preventing direct chemical glycation. Aminoguanidine has been widely used as a diamine oxidase inhibitor [37] . This is an important enzyme regulating polyamine homeostasis and related to several important physiological functions [38] . Aminoguanidine, a reactive hydrazine, seems capable of reacting with pyridoxal phosphate or the pyridoxal enzymes and form hydrazone adducts. Hydrazine derivatives also form DNA adducts [39] and have been claimed to be carcinogenic and genotoxic to the liver and other tissues [40] . The potential secondary effects of any hydrazine drugs should not be totally ignored.
It is interesting to note that in diabetes not only is plasma SSAO activity increased [24] [25] [26] [27] [28] , but it also positively correlates with plasma glycated haemoglobin and urinary albumin excretion [26] . Our findings that MDL-72974A, a selective non-hydrazine SSAO inhibitor, reduces urinary LDH excretion :(a nephropathy indicator) in STZ-induced diabetic'rats and that aminoguanidine strongly inhibits SSAO activity in vivo, suggest that SSAO-catalysed deamination may be related to some of the diabetic complications, such as nephropathy. Unfortunately this study was complicated due to the effect of MDL-72974A on the urinary LDH excretion.
The apparent increase of protein glycation by formaldehyde at low concentration in vitro (Fig.5 ) also suggests the involvement of SSAO-mediated deamination in the formation of AGEs. The mechanism of the formaldehyde effect on protein glycation remains to be explored. Formaldehyde by itself is a well-known protein fixation agent, which is capable of inducing protein crosslinking due to formation of methylene bridges of proteins and thus inducing modification of important structural and functional proteins. The increased production of formaldehyde in the blood from deamination of methylamine could be an alternative mode of increasing blood vessel hardening, which is considered to be a major problem associated with diabetic complication and aging. Interestingly aldehyde dehydrogenase is known to be absent in the plasma [41] , therefore, formaldehyde generated in the blood could not be quickly detoxified.
Advanced glycation is an oxidative process in which free radicals are involved [3] [4] [5] [6] . In fact, diabetes has been considered to be a state of increased oxidative stress (a disturbance of balance between oxidative stress factors and antioxidant factors in favour of the former) [4] . Increases in the levels of circulating lipid peroxides [42] , conjugated dienes [43] , and malonaldehyde [16] have been found to be associated with diabetic atherosclerosis. This hypothesis has been confirmed in a recent finding that hydroxyl free radical is increased in blood and tissues in STZinduced diabetic rats [44] . It is, however, not yet known what triggers the increase in the oxidative stress in diabetes. The increase in SSAO activity in serum or kidney tissues of diabetic patients and animals [23] [24] [25] [26] [27] [28] may relate to this increase in oxidative stress due to excessive deamination. Deamination reactions lead to the production of hydrogen peroxide, which is in turn converted to toxic hydroxyl free radicals via the Fenten reaction in the presence of transition metals [45] . It is interesting to note that SSAO is selectively located in vascular smooth muscles [46, 47] , cartilage [48] and the retina [49] and also circulates in the blood [23] [24] [25] [26] [27] [28] . These tissues are known to be vulnerable to glycation and damage in diabetic patients.
SSAO catalyses the deamination of endogenous alkylamines, such as methylamine [21, 22] and aminoacetone [50] ; toxic formaldehyde and methylglyoxal are produced respectively. SSAO-mediated deamination of methylamine has been demonstrated to be cytotoxic to endothelial cells in vitro [29] . It was also observed that formaldehyde, derived from deamination of methylamine, forms macromolecular adducts and induces protein cross-linking in vivo [51] . It is intriguing that urinary methylamine excretion is enhanced in the diabetic rats (Fig. 4) . This observation is in fact consistent with a classic 1935 report [52] . In this study only three patients were analysed with a rather primitive method. We found approximately twofold increase of urinary methylamine in the diabetic rats, when SSAO activity was blocked by chronic administration of aminoguanidine. If SSAO activity was not blocked, methylamine would be quickly metabolized. The increase of methylamine metabolism in the diabetic rats was less clearly evident. It is possible that the increased SSAO activity in the diabetes may be a result of up-regulation due to increase of SSAO substrates, i.e. methylamine or aminoacetone. It remains to be established how methylamine is increased in diabetes.
Blood methylglyoxal level was found to be significantly increased in diabetic patients [53] . This active endogenous aldehyde also binds and modifies proteins under physiological conditions [54] and has been considered to be cytotoxic and related to diabetic complications [55] . Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking [56] and reduces diabetic nephropathy [15] . Aminoguanidine reacts with methylglyoxal under physiological conditions [57] . It seems to be reasonable to propose that aminoguanidine can also chemically react with and detoxify toxic aldehydes.
In conclusion excessive SSAO-mediated deamination, i. e. in diabetes, would increase the production of toxic aldehydes, such as formaldehyde and methylglyoxal, and enhance oxidative stress, which are in favour of induction of advanced protein glycation. Aminoguanidine can effectively block SSAO activity and/or react with the toxic aldehyde products. This may be, at least partly, related to the reduction of diabetic experimental albuminuria and nephropathy. More investigation is required to substantiate this hypothesis.
